HC Wainwright Issues Positive Outlook for MBRX Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of Moleculin Biotech in a note issued to investors on Friday, August 28th. HC Wainwright analyst S. Nik now expects that the company will post earnings of ($0.45) per share for the quarter, up from their previous forecast of ($1.07). HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($3.01) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.27) EPS and FY2027 earnings at ($0.70) EPS.

MBRX has been the topic of a number of other reports. Wall Street Zen raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Moleculin Biotech has a consensus rating of “Hold” and an average price target of $3.00.

Moleculin Biotech Trading Down 0.8%

NASDAQ:MBRX opened at $0.64 on Tuesday. The company has a market cap of $12.56 million, a PE ratio of -0.09 and a beta of 1.84. Moleculin Biotech has a twelve month low of $0.16 and a twelve month high of $15.75. The company’s 50 day moving average is $1.57 and its two-hundred day moving average is $2.20.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is currently owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.